SU2C hails FDA approval Of Encorafenib + Cetuximab for BRAF V600e-Mutant Metastatic CRC

(Stand Up To Cancer) SU2C welcomed the FDA approval of encorafenib+cetuximab combination for patients with advanced BRAF-mutated CRC. In a Phase 1b/2 clinical trial comparing combinations of encorafenib+cetuximab; and encorafenib+alpelisib+cetuximab in BRAF-mutated CRC, observation by the SU2C-KWF Research Team that patients carrying key mutations in genes associated with the MAP kinase signaling pathway were more responsive supported Breakthrough Therapy Designations for both combination, including encorafenib+cetuximab, for patients with BRAF V600E-mutant metastatic colorectal cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news